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Abstract
Background: Itch is an unpleasant sensation that can be debilitating, especially if it is chronic and of non-
histaminergic origin, as treatment options are limited. Endothelin-1 (ET-1) is a potent endogenous vasoconstrictor
that also has the ability to induce a burning, non-histaminergic pruritus when exogenously administered, by
activating the endothelin A receptor (ETAR) on primary afferents. ET-1 is released endogenously by several cell-types
found in the skin, including macrophages and keratinocytes. Mast cells express ETARs and can thereby be
degranulated by ET-1, and mast cell proteases chymase and carboxypeptidase A3 (CPA3) are known to either
generate or degrade ET-1, respectively, suggesting a role for mast cell proteases in the regulation of ET-1-induced
itch. The mouse mast cell proteases (mMCPs) mMCP4 (chymase), mMCP6 (tryptase), and CPA3 are found in
connective tissue type mast cells and are the closest functional homologs to human mast cell proteases, but little is
known about their role in endothelin-induced itch.
Methods: In this study, we evaluated the effects of mast cell protease deficiency on scratching behavior induced
by ET-1. To investigate this, mMCP knock-out and transgenic mice were injected intradermally with ET-1 and their
scratching behavior was recorded and analyzed.
Results: CPA3-deficient mice and mice lacking all three proteases demonstrated highly elevated levels of scratching
behavior compared with wild-type controls. A modest increase in the number of scratching bouts was also seen in
mMCP6-deficient mice, while mMCP4-deficiency did not have any effect.
Conclusion: Altogether, these findings identify a prominent role for the mast cell proteases, in particular CPA3, in
the protection against itch induced by ET-1.
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Background
Itch is an unpleasant sensation that elicits the desire to
scratch, and is most commonly caused either by light
touch or by substances (pruritogens) that activate itch
receptors on sensory neurons, either directly or indir-
ectly. Histamine is the most extensively studied prurito-
gen, but a large and heterogeneous group of other
pruritogens is also capable of inducing (histamine-inde-
pendent) itch. Such histamine-independent itch can be
challenging to treat effectively, especially in chronic
pruritus [1]. Endothelin-1 (ET-1), a 21-amino acid pep-
tide [2], is the most potent endogenous vasoconstrictor
in the human cardiovascular system [3]. ET-1 can also
induce pain when exogenously administered, and when
lower doses are injected into the skin it can act as a
powerful non-histaminergic pruritogen [4]. Two other
ET isoforms have been identified, endothelin-2 (ET-2),
and endothelin-3 (ET-3) [5], but ET-1 is the most widely
expressed of these [6, 7]. ET-1 is mostly synthesized and
released from vascular endothelial cells [2, 3] but is also
produced by a variety of other cells, such as keratino-
cytes [8], vascular smooth muscle cells [9], dorsal root
ganglia and spinal cord neurons [10, 11], macrophages,
and mast cells [12, 13]. Endothelins bind to two subtypes
of G protein-coupled receptors (GPCRs), the endothelin
A receptor (ETAR) [14] and endothelin B receptor
(ETBR) [15]. In vertebrates, the endothelin receptors are
widely expressed throughout the body, and studies on
both mice and humans have revealed that ETAR has the
highest expression within the cardiovascular system and
the lung, while ETBR is the predominant endothelin re-
ceptor in the brain ([16]; summarized in [3]). Due to its
vasoconstriction properties and high expression within
the cardiovascular system, ET-1 has an important role in
regulating blood pressure [3] but ET-1 can also activate
ETARs on primary afferents (ETAR/Ednra is expressed
in 2-6% of primary afferents [17, 18]) and can transmit
and potentiate both pain and itch [19–23]. Furthermore,
ETARs are found on mast cells and ET-1 is capable of
inducing mast cell degranulation [24, 25].
Mast cells are a part of the immune system and have
an important role in host defense. When activated, they
can degranulate and release a variety of different active
mediators, many of which have pro-inflammatory or
protective functions. Some of these substances, such as
histamine, serotonin, leukotriene C4, and tryptase, can
act directly on receptors on primary afferents as prurito-
gens [26, 27] and it has been suggested that mast cells
are capable of producing ET-1 [12, 13]. Furthermore,
mast cells can release proteases that affect ET-1 and its
production, such as carboxypeptidase A3 (CPA3) that
degrades ET-1 [28, 29] and chymase and Cathepsin E
[30] that can convert the inactive precursor big-ET-1
into active ET-1 [31, 32]. It has previously been shown
that mast cells are necessary for protection against
otherwise fatal ET-1-induced toxicity in mice [33].
In the current study, we investigated the possible in-
volvement of connective tissue mast cell proteases in
ET-1-induced itch, induced by intradermal ET-1 admin-
istration at low (sub-lethal) doses. Our data reveal that
CPA3 and, to a lesser extent, tryptase, play important
roles in the protection against ET-1-induced scratching.
Methods
Generation of transgenic animals
Mice deficient in the mast cell proteases mMCP4
(Mcpt4-/- [34]), mMCP6 (Mcpt6-/- [35]) and CPA3
(Cpa3-/- [36]) were generated as previously described.
Mice deficient in all three proteases
(Mcpt4-/-Mcpt6-/-Cpa3-/-) were then generated by inter-
crossing the above mentioned strains together on a
C57BL/6 J genetic background [37]. The transgenic
Cpa3Y356L,E378A mouse strain, where the protease is ren-
dered inactive by mutating the active sites of the en-
zyme, was generated as previously described [29]. The
accuracy of the transgenic lines has been evaluated in
previous analyses, where each mutation was shown to
result in absence or inactivation of the respective protein
[34–36, 38]. Mice were genotyped by PCR using the fol-
lowing primer combinations: mMCP-4 gene (Mcpt4)
(forward primer, 59-CAA GGT CCA ACTAAC TCC
CTT TGT GCT CC-39, wild-type [WT] reverse, 59-
GGT GAT CTC CAG ATG GGC CAT GTA AGG
GCG-39, knock-out [KO] reverse, 59-GGG CCA GCT
CAT TCC TCC CAC TCA TGA TCT-39), mMCP-6
gene (Tpsb2) (forward primer, 59-TTT AGC TGG ACT
CAG GCT GTG CTC CTC ACT-39, WT reverse, 59-
CTC CTG AAT TGG AGC TAA CCC TGG GAT
TCT-39, KO reverse, 59-GAC CAT GTG ATC GCG
CTT CT-39), and CPA3 gene (Cpa3) (forward primer,
59-GGA CTG TTC ATC CCC AGG AAC C-39, reverse
1, 59-CTG GCG TGC TTT TCATTC TGG-39, reverse
2, 59-GTC CGG ACA CGC TGA ACT TG-39). Wild-
type mice were on a C57BL/6 J genetic background.
Behavior
All behavioral tests were performed on adult (> 7 weeks
old) female and male mice. Control mice were gender-
and age-matched wild-type mice (C57BL/6 J) housed in
the same animal room. All behavior analyses were per-
formed during the day (light) part of a 12 h day/night
cycle, in a controlled environment of 20–24 °C and 45–
65% humidity and by the same female investigator. All
animal procedures were approved by the local ethical
committee in Uppsala and followed the Directive 2010/
63/EU of the European Parliament and of the Council,
The Swedish Animal Welfare Act (SFS 1988:534), The
Swedish Animal Welfare Ordinance (SFS 1988:539), and
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the provisions regarding the use of animals for scientific
purposes: DFS 2004:15 and SJVFS 2012:26.
Itch studies
50 μl of vehicle (0.9% saline, Fresenius Kabi) or
endothelin-1 (20 pmol, Sigma-Aldrich) were injected
intradermally in the back of the neck. Where the ETAR
antagonist BQ-123 was used, 10 pmol of endothelin-1
were injected, with or without 10 nmol of BQ-123
(Sigma-Aldrich) in one intradermal injection. Each
mouse was then placed in a cage with wooden chips and
recorded for 1 h using a digital video camera. After-
wards, AniTracker® v1.2 was used to score the videos for
the duration and frequency of grooming and scratching
behavior. A scratching episode was defined as a bout of
scratching by either hind paw; from the time point it
was lifted until placed back on the ground. The videos
were scored by observers blinded to the genotype and
treatment given. The results for each group are
expressed as the mean frequency of scratching episodes/
60 min, the mean duration of scratching episodes/60
min, and, where relevant, as the mean length of scratch-
ing episodes (total duration/total frequency) and as the
mean frequency of scratching episodes per each 10 min
interval. Results are presented as mean ± SEM.
Statistics
For all sets of data, Gaussian distribution was assessed
by a Shapiro-Wilks test. Student’s t test, two-tailed, was
used to compare two groups. When the groups were
more than two, 1-way ANOVA and either Dunnett’s or
Bonferroni multiple comparison post hoc tests were
used for parametric data, for non-parametric data
Kruskal-Wallis and Dunn’s multiple comparison post
hoc test were used. Two-way repeated measurement
ANOVA with Bonferroni multiple comparison post hoc
test was used to analyze the development of scratching
frequency over time. Grubbs’ test was used to identify
significant outliers (https://www.graphpad.com/quick-
calcs/Grubbs1.cfm, GraphPad Software, Inc.). All other
calculations were performed using Prism version 5.04
(GraphPad Software, Inc., San Diego, CA). Results are
presented as mean ± S.E.M. P values of < 0.05 were con-
sidered significant. In the figures, * refers to P ≤ 0.05, **
refers to P ≤ 0.01, *** refers to P ≤ 0.001, **** refers to P
≤ 0.0001 and n.s. stands for not significant. Lower case
“n” indicates the number of animals used in a set of
experiments.
Results
Mcpt6-/- mice scratch more frequently than controls in
response to vehicle injection
First, Mcpt4-/-, Mcpt6-/-, Cpa3Y356L,E378A,
Mcpt4-/-Mcpt6-/-Cpa3-/- mice and C57BL/6 J controls
were injected with vehicle (0.9% sterile saline) to evaluate
the basal scratching behavior resulting from handling and
injection (Supplementary Fig. 1). The protease-deficient
mice did not differ from controls in response to saline,
with the exception of Mcpt6-/- mice that scratched slightly
more frequently than controls (Supplementary Fig. 1a, P <
0.05), but no differences were observed with regard to
scratching duration in 60min or mean length of scratch-
ing episodes (Supplementary Fig. 1b-1c). This indicates
that Mcpt6-/- mice may in general be more sensitive to
intradermal injections, irrespective of substance injected.
Blocking the ETA receptor significantly decreases ET-1-
induced scratching
ET-1 transmits itch by binding to and activating ETARs on
primary afferents. To exclude possible off-target effects by
ET-1, we administrated the peptide in wild-type mice with
or without the selective ETAR antagonist BQ-123 [39] and
evaluated the scratching behavior. Various different dosage
combinations of ET-1 and BQ-123 have been reported, and
we decided to follow the example of Trentin et al. [20],
where 10 pmol of ET-1 were injected together with 10 nmol
of BQ-123. The antagonist was effective in reducing the
total scratching, with regards to both the frequency of
scratching bouts (Fig. 1a, P < 0.001) and scratching dur-
ation (Fig. 1b, P < 0.001). For reference, the scratching
levels of both treatment groups were compared with
vehicle-injected wild-type controls (data from Supplemen-
tary Fig. 1a-1b). No statistical difference was found between
antagonist-treated and vehicle-injected animals (Fig. 1a, b;
P > 0.05) but a significant difference between ET-1-treated
and vehicle-injected mice was seen (Fig. 1a, b; P < 0.001).
Analysis of scratching frequency over time and in 10-min
intervals with the antagonist treatment as a factor revealed
that scratching was almost completely abolished within the
first 40min in BQ-123-treated mice (Fig. 1c). Post hoc ana-
lysis showed that in the time interval between 10 and 20
min, the difference in scratching frequency between treat-
ment groups became significant (Fig. 1c, P < 0.05). Overall
analysis on scratching frequency with time showed that
BQ-123 was effective in reducing scratching (Fig. 1c, P <
0.05). Taken together, the above results show that BQ-123
blocks ET-1-induced scratching behavior and that ET-1-
induced scratching depends specifically on ETAR activation.
In the group that only received ET-1 (10 pmol), half of the
animals showed only a modest increase in scratching be-
havior (Fig. 1a, b) and therefore it was decided to increase
the dose to 20 pmol in subsequent experiments.
Mcpt4-/-Mcpt6-/-Cpa3-/- mice show profoundly enhanced
scratching behavior when provoked with ET-1
Mouse connective tissue mast cells express mMCP4,
mMCP5, mMCP6, mMCP7, and CPA3 [40] and to in-
vestigate how the loss of connective tissue mast cell-
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specific proteases affects ET-1-induced scratch behavior,
we tested the Mcpt4-/-Mcpt6-/-Cpa3-/- mouse line by
injecting ET-1 intradermally in the nape and compared
them with wild-type controls (Fig. 2a, d). The
Mcpt4-/-Mcpt6-/-Cpa3-/- line lacks the protease mMCP5
as the protein depends on CPA3 for storage [36], and
mMCP7 is only expressed in low levels in mature mast
cells [37], rendering a line that is almost devoid of con-
nective tissue mast cell-specific proteases. In the
Mcpt4-/-Mcpt6-/-Cpa3-/- mice, a large increase in
scratching was seen; in 1 h the protease-deficient mice
scratched on average 1214.0 ± 66 times while the con-
trols had 492.0 ± 70 scratching episodes during the same
time period (Fig. 2a, P < 0.0001). The
Mcpt4-/-Mcpt6-/-Cpa3-/- animal displaying the most ex-
aggerated scratching behavior had more than 2200
scratching episodes during the 60 min; this animal was
found to be a significant outlier according to Grubb’s
test. However, including or excluding that animal did
not affect the statistical significance of the result (P <
0.0001 in both instances, the animal is indicated with a §
in the respective figure). When total scratching duration
was analyzed (Fig. 2b), the results were similar to those
seen for scratching frequency; the protease-deficient
mice spent significantly more time scratching than con-
trols (P < 0.0001). The Mcpt4-/-Mcpt6-/-Cpa3-/- animals
also had shorter scratching episodes on average (Fig. 2c,
P = 0.0025). When the scratching episode frequency was
analyzed over time and in 10-min intervals (Fig. 2d), it
was seen that the Mcpt4-/-Mcpt6-/-Cpa3-/- knockouts
scratched more over time than the controls overall (P <
0.0001) and post hoc testing revealed that the difference
Fig. 1 ET-1-induced scratching is effectively abolished by antagonizing the ETA receptor. Wild-type (C57BL/6 J) mice were injected intradermally
in the nape with either ET-1 (10 pmol, n = 6) or ET-1 together with ETAR antagonist BQ-123 (10 pmol + 10 nmol, n = 6). a, b BQ-123 was very
effective in reducing the total scratching frequency and duration and the scratching behavior was similar to vehicle-injected (saline) animals (n =
24, data from Supplementary Figure 1). c When the frequency results from (a) were analyzed over time with the BQ-123 treatment as a factor, it
was seen that antagonist-treated mice scratched significantly less overall (indicated by significance bar on the far right), and post hoc analysis
showed significant difference between treatment groups in the interval between 10 and 20 min. Results are presented as mean ± SEM. *P ≤ 0.05;
***P ≤ 0.001; n.s., not significant; 1-way ANOVA with Bonferroni multiple comparison (a, b); 2-way ANOVA with Bonferroni multiple comparison
(c). Vehicle data in (a, b) is the same data as presented in Supplementary Figure 1a-1b
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Fig. 2 The mast cell protease-deficient mouse lines Mcpt4-/-Mcpt6-/-Cpa3-/-, Cpa3Y356L,E378A, and Mcpt6-/- scratch more than wild-type controls
when injected with ET-1. a When injected with ET-1 (20 pmol), Mcpt4-/-Mcpt6-/-Cpa3-/- mice (n = 14) had a much higher number of scratching
episodes in 60 min than wild-type controls (WT, n = 12). b Mcpt4-/-Mcpt6-/-Cpa3-/- mice spent more total time scratching during the 60min test. c
The Mcpt4-/-Mcpt6-/-Cpa3-/- mice also had shorter scratching episodes on average than controls. d The results from (a) analyzed over time. The
Mcpt4-/-Mcpt6-/-Cpa3-/- mice scratched more frequently than controls overall (vertical significance bar), and post hoc analysis showed that they
scratched significantly more in the first four intervals of the test. e Both Mcpt6-/- (n = 8) and Cpa3Y356L,E378A mice (Cpa3Y3, n = 8) scratched more
frequently in 60min than wild-type controls (n = 11) when injected with ET-1. Mcpt4-/- mice (n = 7) did not differ from controls in their
scratching behavior. f Mcpt6-/- and Cpa3Y356L,E378A mice also spent more time scratching after ET-1 injection than controls. g But no difference was
seen in the mean length of scratching episodes. h The results from (e) analyzed over time. Both Mcpt6-/- and Cpa3Y356L,E378A mice scratched more
than controls over the duration of the test (indicated by vertical significance bar). Further analysis showed that Cpa3Y356L,E378A mice scratched
more than controls in the intervals between 10 and 40min (indicated by stars), and Mcpt6-/- mice scratched significantly more between 10 and
30min (indicated by #). Results are presented as mean ± SEM. #/*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; n.s, not significant; Student’s t
test (a-c); 2-way ANOVA with Bonferroni multiple comparison (d, h);1-way ANOVA (e-g). Statistical outliers as identified by Grubb’s test are
indicated with the symbol §
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was statistically significant during the first 40 min of the
test (0-10 min: P < 0.01, 10-40 min: P < 0.001). The
above results indicate that the mast cell-specific prote-
ases play an important protective role in ET-1-induced
scratch behavior. A video demonstrating the typical
scratching behavior 10 min. after ET-1 injection in a
wild-type control and a Mcpt4-/-Mcpt6-/-Cpa3-/- mouse
can be found in online Supplementary Materials (Movie
S1).
The Mcpt6-/- and Cpa3Y356L,E378A mouse lines have an
exaggerated scratching response to ET-1
Next, we aimed to identify which of the mast cell prote-
ases was/were responsible for the protective effect against
ET-1-induced scratching. We therefore evaluated the
pruritic effects of an intradermal injection of ET-1 on the
single mast cell protease knock-out lines Mcpt4-/- and
Mcpt6-/-, as well as the transgenic line with enzymatically
inactive CPA3 (Cpa3Y356L,E378A) (Fig. 2e, h).
Cpa3Y356L,E378A mice were initially used in this study
instead of Cpa3-/- mice, since it has been shown that
Cpa3-/- mice also lack mouse mast cell protease 5
(mMCP5) [36] and are thus functionally double-
deficient in enzyme activity. CPA3 has been shown to
protect against ET-1 toxicity in vivo [29]. Here, we noted
that Cpa3Y356L,E378A mice scratched more frequently
than controls during the 60min test (Fig. 2e, P < 0.001).
When scratching duration was analyzed, the findings
were similar (Fig. 2f); the Cpa3Y356L,E378A animals spent
more total time scratching than controls (P < 0.01). No
difference was observed between groups in the mean
length of scratching episodes (Fig. 2g, P > 0.05).
mMCP4 is a chymase, and it has been demonstrated
that mast cell chymase can cleave the inflammatory neu-
ropeptides substance P and vasoactive intestinal peptide
(VIP [41, 42]), both of which can induce itch and de-
granulate mast cells [43–45]. Despite these potential
abilities of mMCP4 to protect against itch, we saw no
difference in scratching frequency, scratching duration
or mean episode length in Mcpt4-/- mice compared with
controls (Fig. 2e, g; P > 0.05), indicating that mMCP4 is
not involved in regulating ET-1-induced scratching. One
Mcpt4-/- animal was a significant outlier in scratching
frequency (Fig. 2e) and another was an outlier in the
mean length of scratching episodes (Fig. 2g). However,
including or excluding these individuals did not have
any effects on the results of the statistical comparison
with controls, i.e., no differences were observed (P >
0.05, the animals are indicated with a § in the respective
figures).
Finally, we investigated the role of the tryp-
tase mMCP6 in ET-1-induced scratching. The analysis
showed that Mcpt6-/- mice scratched more frequently
and spent more time scratching than controls (Fig. 2e,
f; P < 0.05), but the statistical significance was lower
than seen between Cpa3Y356L,E378A mice and controls.
The development of the scratching behavior for all sin-
gle protease transgenic lines was also analyzed over time
in 10-min intervals (Fig. 2 h). The analysis revealed that
both Cpa3Y356L,E378A and Mcpt6-/- animals had more fre-
quent scratching episodes than controls overall during
the test (P = 0.0002), but no difference was observed in
Mcpt4-/- animals (data not shown). Post hoc testing on
the individual intervals showed that the scratching epi-
sode frequency of Cpa3Y356L,E378A mice was elevated
compared with controls in the intervals between 10 and
40min (Fig. 2h, P < 0.001). Mcpt6-/- mice had elevated
scratching frequency compared with controls in the in-
tervals between 10-30 min (Fig. 2h, P < 0.05).
Taken together, the above data indicate that the mast
cell proteases CPA3, and to a smaller extent, mMCP6,
play a role in attenuating ET-1-induced scratching, while
mMCP4 does not.
mMCP5 deficiency does not have an effect on ET-1-
induced scratch behavior
It has previously been shown that CPA3 catalyzes the
breakdown of ET-1 in vitro [29] and is important in redu-
cing the toxic effects of ET-1 administered intraperitone-
ally [29, 33], and our results indicate that CPA3 is also
involved in attenuating the pruritic effects of ET-1 admin-
istered intradermally. The question still remained if the
extensive scratching behavior demonstrated by the
Mcpt4-/-Mcpt6-/-Cpa3-/- mouse line was exclusively the re-
sult of lacking CPA3 and mMCP6. As mentioned above,
when CPA3 is removed from the mast cell, mMCP5 (elas-
tase) is lost as well (at the protein but not mRNA level)
[36]. The Cpa3Y356L,E378A mouse line expresses CPA3 that
is devoid of enzymatic activity and possesses functional
mMCP5, while the Mcpt4-/-Mcpt6-/-Cpa3-/- mouse line
has neither CPA3 nor mMCP5. This prompted the ques-
tion if lacking mMCP5 had any effect on ET-1-induced
scratching. To test this possibility, we performed the ET-1
test on the Cpa3-/- mouse line, which lacks both CPA3
and mMCP5 (Fig. 3a, d). The Cpa3-/- mice had a higher
frequency of scratching bouts than their wild-type coun-
terparts (Fig. 3a, P = 0.0094), and their scratching duration
was elevated vs. controls (Fig. 3b, P = 0.022). There
was no difference between Cpa3-/- mice and controls
in the mean length of scratching episodes (Fig. 3c, P
= 0.904). When the scratching frequency was analyzed
over time and in 10-min intervals (Fig. 3d), it was
seen that the Cpa3-/- mice scratched more than con-
trols overall (P = 0.0094). Post hoc analysis on the in-
tervals revealed that Cpa3-/- mice displayed more
scratching episodes than controls in the interval be-
tween 20 and 30 min (P < 0.001).
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Direct statistical comparison between groups tested at
different time points, using different batches of ET-1, is
not feasible since ET-1 is a very potent peptide that de-
grades with time despite freezer storage. This was con-
firmed by comparing the wild-type controls that were
used in three sets of experiments using different batches
of ET-1, and small but significant differences were found
between the groups (data not shown). However, a visual
comparison of the total scratching frequency in Cpa3-/-
mice, Cpa3Y356L,E378A mice and Mcpt4-/-Mcpt6-/-Cpa3-/-
mice (Fig. 3e), and how the scratching frequency de-
velops over time (Fig. 3f), suggests that Cpa3Y356L,E378A
and Cpa3-/- animals have a similar pattern of scratching be-
havior and magnitude, while the Mcpt4-/-Mcpt6-/-Cpa3-/-
mice show more exaggerated behavior. Together, these
findings indicate that mMCP5 does not contribute to the
protection against the scratching behavior seen in the
Mcpt4-/-Mcpt6-/-Cpa3-/- mice.
Discussion
Here, we investigated the possible involvement of mouse
connective tissue mast cell-specific proteases in the
scratching behavior induced by ET-1. Both mMCP6 and
CPA3 deficiency, as well as the combined loss of
Fig. 3 ET-1-induced scratching is not affected by mMCP5 deficiency. a Cpa3-/- mice (n = 10) are deficient in both CPA3 and mMCP5, and had
more frequent scratching bouts in 60 min than wild-type controls (WT, n = 10) when injected with ET-1 (20 pmol). b Cpa3-/- mice also spent more
time scratching during the 60min. c No difference was seen between genotypes in the mean length of scratching episodes. d When the
frequency results from (a) were analyzed over time, it was seen that Cpa3-/- mice scratched significantly more than controls overall (indicated by
vertical significance bar), and post hoc analysis showed a significant difference in the interval between 20 and 30min. e, f Visual comparison of
the total frequency of scratching episodes and scratching frequency development over time, between Cpa3-/- mice (data from (a)), Cpa3Y356L,E378A
mice (Cpa3Y3, data from Fig. 2e) and Mcpt4-/-Mcpt6-/-Cpa3-/- mice (data from Fig. 2a). The two CPA3-deficient mouse lines follow a similar
scratching pattern and magnitude, while the Mcpt4-/-Mcpt6-/-Cpa3-/- mice demonstrate more exaggerated behavior. Results are presented as
mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, Student’s t test (a-c), 2-way ANOVA with Bonferroni multiple comparison (d)
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mMCP4, mMCP6 and CPA3, resulted in significantly in-
creased scratching behavior compared with wild-type
controls, while mMCP4-deficiency alone did not have an
effect. We could also conclude that mMCP5 is not in-
volved in ET-1-induced scratching behavior.
ET-1 induces itch and pain through the ETA receptor on
primary afferents
ET-1 binds to and activates the G protein-coupled recep-
tors ETAR and ETBR [46], and in humans it can cause
pain, hyperalgesia, and intense pruritus when exogenously
administered, depending on the dose and the route of ad-
ministration [22, 23, 47]. In the periphery, it has been re-
ported that ETAR is mainly responsible for pain and itch
transmission, while ETBR has generally been coupled to
analgesic and antipruritic effects [20, 48, 49]. Similar to
what has been seen with other algogens, central adminis-
tration of ET-1 induces analgesia, which is mediated
through both ETAR and ETBR [50]. Since animals cannot
describe their sensations, a useful behavioral model to dis-
tinguish between algogens and pruritogens has been de-
veloped in mice: the mouse cheek model [51]. In this
model, a substance is injected intradermally in the cheek
and if the substance is an algogen the mouse responds to
the pain by wiping the face with its forepaws, while pruri-
togens will elicit scratches by the hind paws. When ET-1
was tested in the cheek test, the mice exhibited both pain
and itch behaviors [21], indicating that ET-1 is a sub-
stance that can induce both sensations. This suggests
that the particular sensation experienced upon injec-
tion of ET-1 has certain painful properties experi-
enced by the animals, a feeling that human volunteers
have described as “burning itch” [22]. Furthermore,
ET-1 is capable of degranulating mast cells through
ETAR, causing release of pruritogens such as hista-
mine and leukotriene C4 [24, 25, 52]. However, ET-1-
induced itch is generally considered to be non-
histaminergic. It depends upon other neuronal signal-
ing mechanisms than histamine [49, 53] and hista-
mine 1 receptor antagonists have little effect on the
scratching behavior [20, 49]. Degranulation also re-
leases large amounts of mast cell proteases, which
have been reported to have both protective and in-
flammatory properties [40, 54, 55].
Multiple mast cell protease deficiency and ET-1-induced
scratching
Mcpt4-/-Mcpt6-/-Cpa3-/- mice lack all connective tissue
type mast cell-specific proteases, and this results in ab-
normal mast cell secretory granule composition and
morphology, as well as reduction in heparin content
[37]. It is therefore not surprising that these animals
have abnormal physiological, and consequently, behav-
ioral, responses to provocation. In our study, we saw
greatly increased scratching behavior upon ET-1 injec-
tion in Mcpt4-/-Mcpt6-/-Cpa3-/- mice compared with
controls, indicating that mast cell-specific proteases
serve an important function in attenuating the itch in-
duced by the peptide. In order to evaluate the contribu-
tion from the individual proteases, however, we also
assessed mice with single deficiency of the respective
proteases.
These analyses revealed that both Cpa3Y356L,E378A and
Mcpt6-/- animals scratched significantly more than con-
trols in response to ET-1, but the Mcpt4-/-Mcpt6-/-Cpa3-/-
mouse line exhibited scratching that was of an even
greater magnitude. Since the Mcpt4-/-Mcpt6-/-Cpa3-/-
mouse line is lacking both mMCP6 and CPA3, a certain
additive effect was not unexpected but this prompted the
question if the intense scratching behavior was only due
to the lack of these two proteases, or if mMCP5-
deficiency also played a role. mMCP5 is a mast cell elas-
tase which has not been extensively studied and no con-
nection to itch has been reported, but it has been shown
to have a role in mediating epidermal burn injuries in
mice [56]. Since Mcpt4-/-Mcpt6-/-Cpa3-/- mice lack CPA3,
they also lose the ability to store the elastase mMCP5. To
investigate the potential properties of mMCP5, the ET-1
test was also performed on Cpa3-/- mice (that lack both
CPA3 and mMCP5), to see if their scratching behavior
would follow a similar pattern and magnitude as seen in
Cpa3Y356L,E378A mice (that possess mMCP5 but enzymati-
cally non-functional CPA3) or Mcpt4-/-Mcpt6-/-Cpa3-/-
mice. However, the results from the Cpa3-/- mice did not
resemble the greatly enhanced scratching seen in the mul-
tiple protease-deficient mice. This indicates that mMCP5
does not have an important role in the protection against
ET-1-induced scratching.
CPA3 and ET-1-induced scratch behavior
CPA3 is not as well studied as mMCP4 and mMCP6,
and has mainly received attention for its role in host
defense by cleaving a particular type of toxins, sarafotox-
ins, that can be found in snake and bee venom [29, 57].
Sarafotoxins belong to the endothelin family and it has
been demonstrated that CPA3 cleaves both sarafotoxin
S6b and ET-1 at the C-terminal, which results in in-
active and non-toxic products [29]. Mast cell chymase
also cleaves those substrates, but at an internal location,
which is not sufficient to reduce the toxicity [29]. CPA3
is necessary to protect against otherwise fatal ET-1 tox-
icity when it is injected intraperitoneally in doses be-
tween 1 and 3 nmols [29, 33]. In the current study, a
considerably lower dose of ET-1 (20 pmol) and another
route of administration (intradermal) were used to inves-
tigate ET-1-induced itch instead of toxicity, and our re-
sults show that CPA3-deficiency results in significantly
exaggerated scratching behavior compared with controls.
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This result was seen in all the mouse lines that lack
functional CPA3: Cpa3Y356L,E378A, Cpa3-/-, and
Mcpt4-/-Mcpt6-/-Cpa3-/-. This suggests that CPA3 has an
important role in protection against exogenously admin-
istered ET-1 with regard to pruritus.
mMCP4 and ET-1-induced scratch behavior
Chymase has the capability to produce ET-1 by cleaving
the precursor peptide Big-ET-1 in vivo [58]. Chymase has
also been reported to cleave known itch mediators such as
interleukins 6, 13, and 33 (IL-6, IL-13, IL-33 [59, 60]) as
well as substance P and VIP [41–43]. Despite these prop-
erties, there is little data that links mMCP4 directly to
pruritus, but studies have shown that chymase inhibition
is successful in attenuating itch and skin inflammation in
a mouse AD model [61, 62]. In our study, no effects of
chymase on ET-1-induced scratching behavior were ob-
served. This is in accordance with a previous study show-
ing that mMCP4 knockouts have the same resistance to
ET-1-like toxicity (induced by sarafotoxins) as wild-type
controls, while the toxicity was fatal in mast cell-deficient
mice [57].
mMCP6 and ET-1-induced scratch behavior
Mcpt6-/- mice demonstrated higher levels of scratching
behavior than controls in response to ET-1. This could
potentially be explained by direct ET-1 inactivation cata-
lyzed by mMCP6. Alternatively, mMCP6 could affect
signaling events downstream of the binding of ET-1 to
its receptor. Human tryptase has been reported to cleave
CGRP in vitro in an efficient manner [63] and ET-1 in-
duces the release of CGRP and glutamate from primary
afferents through ETAR activation [64]. Since CGRP has
been implicated in itch modulation [65, 66], mMCP6
may have an effect on ET-1-induced scratch behavior in-
directly, through the degradation of CGRP. However,
the Mcpt6-/- mice may also be more sensitive to the in-
jection of an inert vehicle (Supplementary Fig. 1a), which
further complicates the interpretation of their scratching
behavior.
Conclusions
Here, we have investigated the effects of connective tis-
sue mast cell protease deficiency on ET-1-induced
scratching behavior. We found that the mast cell car-
boxypeptidase CPA3 was critical for attenuating ET-1-
induced scratching, and our data also indicate that mast
cell tryptase can contribute to such protection. Import-
antly, the protease expression profile of mouse and hu-
man skin mast cells is highly analogous and the
substrate specificities of the corresponding mouse and
human mast cell proteases are closely related [40, 55],
and it is therefore likely that human mast cell proteases
have a similar impact on itch as seen in the approach
adopted here. Altogether, these findings establish a novel
principle for how itch responses can be regulated. Intri-
guingly, since mast cells are also strongly implicated in
promoting itch signaling (e.g., by secreting histamine
and serotonin), our present investigations introduce the
notion that mast cells can both promote and attenuate
itch.
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Additional file 1: Figure S1. mMCP6-deficient mice potentially scratch
more than controls in response to vehicle injection. a) Mcpt6-/- mice (n = 6)
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Mcpt4-/-Mcpt6-/-Cpa3-/- mice (n = 10) did not. b) No difference was seen
between groups in scratching duration after vehicle injection, c) or in
mean length of scratching episodes. Vehicle data for controls are pooled
from three different experiments. Results are presented as mean ± SEM.
*P ≤ 0.05, Kruskal-Wallis. Statistical outliers as identified by Grubb’s test
are indicated with the symbol §.
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